Insight Molecular Diagnostics Inc. 8-K

What Happened

• Insight Molecular Diagnostics Inc. filed an 8-K on Feb. 26, 2026 disclosing that on February 20, 2026 the company entered into a Specimen Collection Agreement with Quest Diagnostics Incorporated.
• Under the agreement, Quest will provide specimen collection–related services for specimens used for the company’s GraftAssureCore™ test, a blood test that measures donor‑derived cell‑free DNA (dd‑cfDNA) using a novel PCR‑based platform. The agreement provides for fees to be paid to Quest for services rendered.
• The parties also agreed to use commercially reasonable efforts, for a specified period, to negotiate in good faith additional rights related to the GraftAssure technology. The company intends to file the full agreement as an exhibit to a future report.

Key Details

• Date of agreement: February 20, 2026 (8-K filed Feb. 26, 2026).
• Counterparty: Quest Diagnostics Incorporated will provide specimen collection services.
• Service focus: Specimens for GraftAssureCore dd‑cfDNA testing (PCR‑based platform).
• Contract features: Fees payable to Quest; parties will negotiate potential additional rights to the technology for a set period; full agreement to be filed later.

Why It Matters

• This agreement addresses a practical step toward clinical testing and sample logistics by partnering with an established national lab, which can help streamline specimen collection and patient enrollment for GraftAssureCore testing.
• It is a services agreement (not a licensing or revenue-sharing deal as disclosed); financial terms and the outcome of any further negotiations over technology rights were not disclosed, so investors should note there is no immediate revenue detail or material licensing commitment in this filing.
• If subsequent negotiations lead to broader collaboration or licensing, that could be materially important, but this 8-K reports only the specimen services arrangement and the intent to negotiate additional rights.